PHARMACEUTICAL IP

  • Our Offering
    • Fractional IP counsel
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
    • Oppositions and appeals
  • Fractional IP counsel
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapy
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional IP counsel
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
    • Oppositions and appeals
  • Fractional IP counsel
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapy
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional IP counsel
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional IP counsel
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

Lack of clarity by the backdoor: An ambiguity “may simply result in a broader interpretation” (T 0977/25)

  • Sector: Patent law
  • 4th October 2026
In T 0977/25, a Board of Appeal found that the word "it" in an amended method claim for an e-cigarette cartridge was ambiguous.

Originally posted on IPKat.

For those wondering about the risks of inconsistencies and description amendments following the G1/24 and G1/25 duo, the Board of Appeal also found that an “unresolved ambiguity” in the claims added subject-matter by virtue of the fact that both possible interpretations were considered covered by the claim. 

Legal background: Ambiguity and added matter, a divided case law

Article 123(2) EPC prohibits amendments that extend beyond the content of the application as filed. The test is the “gold standard” of G 2/10: what the skilled person would derive directly and unambiguously from the application as filed.

The intention of the referring Board in G 1/26 is to resolve confusion in the case law over how ambiguous claim interpretations interact with the added matter test. T 1791/16 held that all technically reasonable interpretations of an ambiguous claim must be considered, and that if any one of them extends beyond the application as filed, there is added matter. A different line of case law, including T 367/20, says that the claim should first be interpreted by the skilled person, and only then compared against the application as filed. We also, of course, now have the decision of the EBA in G 1/24 that the description must always be “consulted” when interpreting the claims (Evolve Insights).

This divergence led to the referral in T 873/24, now pending as G 1/26 (Evolve Insights). Question 3(a) of G1/26 asks whether a claim term must be assessed for added matter against all interpretations that make technical sense on the basis of the claim alone. Question 3(b) asks, if this is not the case, whether if it sufficient that only the interpretations of the subject-matter of the claim established against the background of the patent specification as a whole are directly and unambiguously derivable from the application as filed. 

Notably, the recent decision in G 1/25 went a fair way towards answering the G 1/26 questions on claim interpretation, confirming that interpretation is a single process and that the description cannot impose a limitation for which the claim wording provides no basis. The added matter question, however, was left without a direct answer (Evolve Insights).

Case background: Back to cigarettes

In this case we are unfortunately back to the rather uninspiring subject matter of cigarette inventions (who knew there was so much important innovation in the field…). Philip Morris’s patent, EP 3288403 B1, related to a cartridge (or “cartomiser”) for an e-cigarette. The cartridge was specified as combining a housing holding the liquid substrate with a heater assembly, the heater element of which extends across the opening of the housing and has apertures of different sizes. Nicoventures Trading Limited opposed. The Opposition Division maintained the patent in amended form, and the Patentee appealed. The key prior art was an earlier-filed but later-published international application, relevant to novelty only under Article 54(3) EPC.

Providing or fixing

Claim 12 as granted was a method of manufacturing the cartridge, requiring only “providing” a storage portion, filling it, and “providing” a heater assembly extending across the opening. The Patentee argued that the skilled person would read the claim as requiring the heater assembly to be fixed to the housing, as the only technically reasonable reading.

The Board of Appeal was not convinced, finding that “The notion of “providing” per se covers the mere act of “making available”” (r. 5). However, having consulted the description, the Board of Appeal concluded that “Claim 12 has thus deliberately been formulated without indicating how the “provided” components are further handled in the claimed manufacturing method” (r. 7.3).

The decision was taken at oral proceedings on 30 July 2026, before G 1/25 issued on 3 September 2026. The written reasons nonetheless added that the Board of Appeal had not “used the description or drawings to impose on claim 12 a limitation for which the claim wording provides no basis” (r. 7.5), in line with G 1/25. Critically, only one paragraph expressly stated that the heater assembly was fixed to the housing. Interpreted broadly, claim 12 was found to lack novelty and the main request rejected. For this Board at least, G1/25 did not change things but simply confirmed G1/24 on the matter of claim interpretation.

What is “it”?

The Patentee’s first auxiliary request amended claim 12 to require “fixing a heater assembly comprising at least one heater element to the open end of the housing so that it extends across the opening of the housing”. Including the “fixing” feature restored novelty. The Opponent cited a problem with the pronoun “it”, saying that it was ambiguous.

The Board of Appeal agreed that “the term “it” in claim 12 was indeed unclear. Grammatically, “it” as used on the claim was found to be a possible reference either to the heater assembly or to the heater element” (r. 27). Both readings made technical sense, in the view of the Board of Appeal, and both were considered compatible with the description. Consulting the description was therefore considered of no help. It was found that the application as filed disclosed the heater element extending across the opening, but not the heater assembly as a whole.

An unresolved ambiguity is a broader claim

Neither party had asked for a stay pending G 1/26. The Board of Appeal therefore went ahead to assess whether the ambiguity added matter. The Board first rejected the two-step approach of T 367/20 and T 847/24, which it considered appeared to require that any ambiguity must first be resolved by interpretation before compliance with Article 123(2) EPC can be assessed. For the Board of Appeal in the present case, such an approach implies that, in case of ambiguities, a claim must be interpreted in such a way that no violation of Article 123(2) EPC arises, an approach it resoundingly rejected: “compliance with Article 123(2) EPC cannot be a precondition for the correct claim interpretation, but must instead be assessed after that interpretation has been established” (r. 31).

The Board of Appeal, however, also chose not to treat an unresolved ambiguity as leaving the interpretation “open”. Rather, the Board of Appeal considered, “an unresolved ambiguity may simply result in a broader interpretation” (r. 32). The Board of Appeal in this case therefore gave a clear “yes” to Question 3(a) of G1/26. For this Board of Appeal, where the meaning of the claim is ambiguous, the claim is considered to cover all of them. 

Claim 12 was thus read as if it said that “[the heater assembly or the heater element]” extends across the opening (r. 33). One of these alternative interpretations of the claims was found to lack basis and the claim therefore to add matter. In other words, a unsolved ambiguity should be construed as claiming both alternatives. This approach fits with the guidance to examiner’s on how to apply G1/24. 

The Patentee was able to rescue the patent by deleting the method claims at the oral proceedings. The Board of Appeal admitted this late request under Article 13(2) RPBA, as the ambiguity objection had only been raised at the hearing. The product claims were found novel, and the case was remitted to the Opposition Division for inventive step.

Analysis

In this case, the Board of Appeal found that if a reading of the claim in consultation of the description leads to two possible interpretations, the claim must be considered to cover both and both interpretations must have basis. This is a serious risk of patentees in conjunction with the EPO’s added matter rule. Interestingly, whilst lack of clarity is not a ground of opposition, added matter very much is. Ambiguity leading to added matter therefore seems a way that opponents may bring a clarity objection at opposition via the back-door. 

The decision also suggests the circumstances where amending the description can leave you in a worse position post-grant from an added matter perspective. In this case, the patentee had a problem with added matter. However, this was not an inescapable trap because the ambiguity in the claims was left unresolved (and so any post-grant amendment to resolve the ambiguity would be narrowing). An ambiguous claim covering “A or B” is broad. Limiting to either A or B would be narrowing and Art 123(3) does not become a problem. The fatal case is the one where the description is amended in line with the claims in a way that inadvertently is aligned to subject matter that was not in the application as filed (e.g. by narrowing a broader definition leading to an intermediate generalisation). By this reasoning, a vague description is survivable by narrowing amendment, whilst a clarified, consistent and adapted description may leave you in an inescapable added matter trap. 

We now have to wait to see if the EBA will agree with the Board of Appeal in this case.

Author: Rose Hughes

Rose is a biotech and pharmaceutical patent specialist with over a decade of experience in intellectual property. Rose is a patent attorney at Evolve, where she leverages our unique fractional in-house model to provide clients with deep patent law expertise combined with the strategic commercial oversight typically associated with senior in-house counsel.

With a PhD in Immunology from UCL, Rose applies her technical background to complex innovations in biologics, cell and gene therapies, and the rapidly emerging field of AI-assisted drug development. Previously, Rose held the role of Director. Patents at AstraZeneca, where she was responsible for global IP portfolios and IP strategy at every stage of the pharmaceutical pipeline, from platform development and on-market commercialization to SPCs and patent term extensions.

A recognized thought leader in the field, Rose has been a regular contributor to IPKat since 2018, offering practical insights into European patent law developments. She is also a frequent speaker on the epi podcast, a guest lecturer for the Brunel University IP law Postgrad Certificate, and a contributing author to published books A User’s Guide to Intellectual Property in Life Sciences (2021) and Developments and Directions in Intellectual Property Law (2023).

Related insights...

G1/25: What are the consequences?

  • 12th September 2026
Following the release of G1/25, questions have been circling as to what the decision means for the pending referral in G 1/26 and what the consequences (good or bad) are for applicants and patentees.

BREAKING: When real doubt hits – G1/25 changes the description adaptation requirement for the worse

  • 4th September 2026
G 1/25, issued today, holds that the description must be adapted only where an “inconsistency” between the claims and description causes non-compliance with another requirement of the EPC.

New referral on claim interpretation and relevance of G1/24 to added matter confirmed (G1/26)

  • 23rd July 2026
We now have confirmation of a new referral to the EBA on claim interpretation (G1/26). As previously hinted, The Board of Appeal in T 0873/24 has decided to refer questions on the application of G1/24 to the assessment of added matter.

When do you file for a drug combination invention? (T592/24)

  • 16th July 2026
Drug combination inventions are increasingly difficult to protect. File too early for a drug-combination invention and the application may lack the data to support the non-obvious effect of the combination. Wait for the trial read-out, and a competitor, or your own published protocol, may have already placed the invention in the public domain. 

Patenting the use of medical devices (T0941/24)

  • 26th June 2026
Patenting medical devices in Europe is challenging. First, there is the problem that medical use claims are not permitted for medical devices, whilst simultaneously methods of treatment or surgery using a device are excluded from patentability. 

BREAKING: Imminent new referral to the EBA on the relevance of G1/24 to added matter

  • 6th May 2026
The Board of Appeal in T 873/24 has decided to refer questions to the Enlarged Board of Appeal (EBA) on the application of G1/24 (claim interpretation) to the assessment of added matter.

Description amendments can extend protection (T 439/22)

  • 3rd April 2026
The comments space for the last IPKat article on claim interpretation/description amendments appears to have maxed out. Sorry everyone, but maybe it’s for the best. However, fear not, we now have a new decision to restart the debate!

The validity and value of cell therapy safety protocol inventions (T 1555/23)

  • 11th March 2026
The patent in T 1555/23 is impressively broad. The claims covered a medical use invention comprising treating the side effects of CAR-T cell therapy using the now industry-standard class of cytokine inhibitor. The claim was not limited to any particular CAR-T cell therapy, target, type of cancer or specific inhibitor.

G 1/25 (description amendments) amicus curiae: The battle lines are drawn

  • 4th March 2026
If you want to start an argument amongst European patent attorneys, just mention description amendments. As the comments on this and other blogs attest, adaptation of the description is a highly divisive issue and the debate can get decidedly heated (with our US colleagues looking on with bemusement).

Mechanistic insights supporting the sufficiency and inventive step of a therapeutic use (without clinical data) (T 1601/22)

  • 24th February 2026
At the EPO, it is perfectly possible for a therapeutic invention to survive without clinical data. The recent decision in T 1601/22 confirmed this sometimes surprisingly low bar for sufficiency in Europe for therapeutic invention.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

Subscribe

Contact Us